Please login to the form below

Not currently logged in
Email:
Password:

Stallergenes appoints Christian Chavy CEO

He will replace Roberto Gradnik at the end of this month

Christian Chavy has been appointed CEO of French biopharmaceutical company Stallergenes and will take over from Roberto Gradnik at the end of this month.  

Chavy has worked for the ARES Life Science healthcare investment fund since 2010 and prior to that he served as president of global operations for Actelion Pharmaceuticals.  

Before joining Actelion he was vice president of Serono's reproductive medicine strategic unit and chairman of the company's French subsidiary.

Stallergenes said Chavy's appointment would enable it to “pursue its strategy” and to its work in promising immunotherapy markets – the US in particular.  

Meanwhile Gradnick, who joined Stallergenes in October 2011 as deputy CEO before taking up the post of CEO three months later, will provide consultancy services to the board of directors during a four-month transitional period.

7th March 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics